FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947734585> ?p ?o ?g. }

• W2947734585 endingPage "1034" @default.
• W2947734585 startingPage "1023" @default.
• W2947734585 abstract "BackgroundAlveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discriminate the effect of cediranib from the intrinsically indolent nature of ASPS.MethodsIn this double-blind, placebo-controlled, randomised, phase 2 trial, we recruited participants from 12 hospitals in the UK (n=7), Spain (n=3), and Australia (n=2). Patients were eligible if they were aged 16 years or older; metastatic ASPS that had progressed in the previous 6 months; had an ECOG performance status of 0–1; life expectancy of more than 12 weeks; and adequate bone marrow, hepatic, and renal function. Participants had to have no anti-cancer treatment within 4 weeks before trial entry, with exception of palliative radiotherapy. Participants were randomly assigned (2:1), with allocation by use of computer-generated random permuted blocks of six, to either cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Treatment was supplied in number-coded bottles, masking participants and clinicians to assignment. Participants were unblinded at week 24 or sooner if they had progression defined by Response Evaluation Criteria in Solid Tumors (version 1.1); those on placebo crossed over to cediranib and all participants continued on treatment until progression or death. The primary endpoint was percentage change in sum of target marker lesion diameters between baseline and week 24 or progression if sooner, assessed in the evaluable population (all randomly assigned participants who had a scan at week 24 [or sooner if they progressed] with target marker lesions measured). Safety was assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01337401; the European Clinical Trials database, number EudraCT2010-021163-33; and the ISRCTN registry, number ISRCTN63733470 recruitment is complete and follow-up is ongoing.FindingsBetween July 15, 2011, and July 29, 2016, of 48 participants recruited, all were randomly assigned to cediranib (n=32) or placebo (n=16). 23 (48%) were female and the median age was 31 years (IQR 27–45). Median follow-up was 34·3 months (IQR 23·7–55·6) at the time of data cutoff for these analyses (April 11, 2018). Four participants in the cediranib group were not evaluable for the primary endpoint (one did not start treatment, and three did not have their scan at 24 weeks). Median percentage change in sum of target marker lesion diameters for the evaluable population was −8·3% (IQR −26·5 to 5·9) with cediranib versus 13·4% (IQR 1·1 to 21·3) with placebo (one-sided p=0·0010). The most common grade 3 adverse events on (blinded) cediranib were hypertension (six [19%] of 31) and diarrhoea (two [6%]). 15 serious adverse reactions in 12 patients were reported; 12 of these reactions occurred on open-label cediranib, and the most common symptoms were dehydration (n=2), vomiting (n=2), and proteinuria (n=2). One probable treatment-related death (intracranial haemorrhage) occurred 41 days after starting open-label cediranib in a patient who was assigned to placebo in the masked phase.InterpretationGiven the high incidence of metastatic disease and poor long-term prognosis of ASPS, together with the lack of efficacy of conventional chemotherapy, our finding of significant clinical activity with cediranib in this disease is an important step towards the goal of long-term disease control for these young patients. Future clinical trials in ASPS are also likely to involve immune checkpoint inhibitors.FundingCancer Research UK and AstraZeneca. Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discriminate the effect of cediranib from the intrinsically indolent nature of ASPS. In this double-blind, placebo-controlled, randomised, phase 2 trial, we recruited participants from 12 hospitals in the UK (n=7), Spain (n=3), and Australia (n=2). Patients were eligible if they were aged 16 years or older; metastatic ASPS that had progressed in the previous 6 months; had an ECOG performance status of 0–1; life expectancy of more than 12 weeks; and adequate bone marrow, hepatic, and renal function. Participants had to have no anti-cancer treatment within 4 weeks before trial entry, with exception of palliative radiotherapy. Participants were randomly assigned (2:1), with allocation by use of computer-generated random permuted blocks of six, to either cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Treatment was supplied in number-coded bottles, masking participants and clinicians to assignment. Participants were unblinded at week 24 or sooner if they had progression defined by Response Evaluation Criteria in Solid Tumors (version 1.1); those on placebo crossed over to cediranib and all participants continued on treatment until progression or death. The primary endpoint was percentage change in sum of target marker lesion diameters between baseline and week 24 or progression if sooner, assessed in the evaluable population (all randomly assigned participants who had a scan at week 24 [or sooner if they progressed] with target marker lesions measured). Safety was assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01337401; the European Clinical Trials database, number EudraCT2010-021163-33; and the ISRCTN registry, number ISRCTN63733470 recruitment is complete and follow-up is ongoing. Between July 15, 2011, and July 29, 2016, of 48 participants recruited, all were randomly assigned to cediranib (n=32) or placebo (n=16). 23 (48%) were female and the median age was 31 years (IQR 27–45). Median follow-up was 34·3 months (IQR 23·7–55·6) at the time of data cutoff for these analyses (April 11, 2018). Four participants in the cediranib group were not evaluable for the primary endpoint (one did not start treatment, and three did not have their scan at 24 weeks). Median percentage change in sum of target marker lesion diameters for the evaluable population was −8·3% (IQR −26·5 to 5·9) with cediranib versus 13·4% (IQR 1·1 to 21·3) with placebo (one-sided p=0·0010). The most common grade 3 adverse events on (blinded) cediranib were hypertension (six [19%] of 31) and diarrhoea (two [6%]). 15 serious adverse reactions in 12 patients were reported; 12 of these reactions occurred on open-label cediranib, and the most common symptoms were dehydration (n=2), vomiting (n=2), and proteinuria (n=2). One probable treatment-related death (intracranial haemorrhage) occurred 41 days after starting open-label cediranib in a patient who was assigned to placebo in the masked phase. Given the high incidence of metastatic disease and poor long-term prognosis of ASPS, together with the lack of efficacy of conventional chemotherapy, our finding of significant clinical activity with cediranib in this disease is an important step towards the goal of long-term disease control for these young patients. Future clinical trials in ASPS are also likely to involve immune checkpoint inhibitors." @default.
• W2947734585 created "2019-06-07" @default.
• W2947734585 creator A5003031523 @default.
• W2947734585 creator A5006616764 @default.
• W2947734585 creator A5006665510 @default.
• W2947734585 creator A5006933759 @default.
• W2947734585 creator A5009838798 @default.
• W2947734585 creator A5011342082 @default.
• W2947734585 creator A5020381519 @default.
• W2947734585 creator A5020934507 @default.
• W2947734585 creator A5038603211 @default.
• W2947734585 creator A5043324898 @default.
• W2947734585 creator A5043736497 @default.
• W2947734585 creator A5043795014 @default.
• W2947734585 creator A5044876866 @default.
• W2947734585 creator A5051920004 @default.
• W2947734585 creator A5053304892 @default.
• W2947734585 creator A5055983682 @default.
• W2947734585 creator A5057465917 @default.
• W2947734585 creator A5060130360 @default.
• W2947734585 creator A5069270463 @default.
• W2947734585 creator A5069678519 @default.
• W2947734585 creator A5078484307 @default.
• W2947734585 creator A5078791888 @default.
• W2947734585 date "2019-07-01" @default.
• W2947734585 modified "2023-09-30" @default.
• W2947734585 title "Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial" @default.
• W2947734585 cites W1187020812 @default.
• W2947734585 cites W1987717836 @default.
• W2947734585 cites W2003842905 @default.
• W2947734585 cites W2007624605 @default.
• W2947734585 cites W2009240587 @default.
• W2947734585 cites W2060628991 @default.
• W2947734585 cites W2067259108 @default.
• W2947734585 cites W2111058811 @default.
• W2947734585 cites W2121534113 @default.
• W2947734585 cites W2122492414 @default.
• W2947734585 cites W2133365073 @default.
• W2947734585 cites W2146355396 @default.
• W2947734585 cites W2163672915 @default.
• W2947734585 cites W2740911849 @default.
• W2947734585 cites W2759823725 @default.
• W2947734585 cites W2773047103 @default.
• W2947734585 cites W2808043936 @default.
• W2947734585 cites W2944423827 @default.
• W2947734585 cites W298677108 @default.
• W2947734585 doi "https://doi.org/10.1016/s1470-2045(19)30215-3" @default.
• W2947734585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6602919" @default.
• W2947734585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31160249" @default.
• W2947734585 hasPublicationYear "2019" @default.
• W2947734585 type Work @default.
• W2947734585 sameAs 2947734585 @default.
• W2947734585 citedByCount "63" @default.
• W2947734585 countsByYear W29477345852019 @default.
• W2947734585 countsByYear W29477345852020 @default.
• W2947734585 countsByYear W29477345852021 @default.
• W2947734585 countsByYear W29477345852022 @default.
• W2947734585 countsByYear W29477345852023 @default.
• W2947734585 crossrefType "journal-article" @default.
• W2947734585 hasAuthorship W2947734585A5003031523 @default.
• W2947734585 hasAuthorship W2947734585A5006616764 @default.
• W2947734585 hasAuthorship W2947734585A5006665510 @default.
• W2947734585 hasAuthorship W2947734585A5006933759 @default.
• W2947734585 hasAuthorship W2947734585A5009838798 @default.
• W2947734585 hasAuthorship W2947734585A5011342082 @default.
• W2947734585 hasAuthorship W2947734585A5020381519 @default.
• W2947734585 hasAuthorship W2947734585A5020934507 @default.
• W2947734585 hasAuthorship W2947734585A5038603211 @default.
• W2947734585 hasAuthorship W2947734585A5043324898 @default.
• W2947734585 hasAuthorship W2947734585A5043736497 @default.
• W2947734585 hasAuthorship W2947734585A5043795014 @default.
• W2947734585 hasAuthorship W2947734585A5044876866 @default.
• W2947734585 hasAuthorship W2947734585A5051920004 @default.
• W2947734585 hasAuthorship W2947734585A5053304892 @default.
• W2947734585 hasAuthorship W2947734585A5055983682 @default.
• W2947734585 hasAuthorship W2947734585A5057465917 @default.
• W2947734585 hasAuthorship W2947734585A5060130360 @default.
• W2947734585 hasAuthorship W2947734585A5069270463 @default.
• W2947734585 hasAuthorship W2947734585A5069678519 @default.
• W2947734585 hasAuthorship W2947734585A5078484307 @default.
• W2947734585 hasAuthorship W2947734585A5078791888 @default.
• W2947734585 hasBestOaLocation W29477345851 @default.
• W2947734585 hasConcept C126322002 @default.
• W2947734585 hasConcept C142724271 @default.
• W2947734585 hasConcept C168563851 @default.
• W2947734585 hasConcept C204787440 @default.
• W2947734585 hasConcept C27081682 @default.
• W2947734585 hasConcept C2777666782 @default.
• W2947734585 hasConcept C2778256501 @default.
• W2947734585 hasConcept C2778629024 @default.
• W2947734585 hasConcept C2991744798 @default.
• W2947734585 hasConcept C71924100 @default.
• W2947734585 hasConceptScore W2947734585C126322002 @default.
• W2947734585 hasConceptScore W2947734585C142724271 @default.
• W2947734585 hasConceptScore W2947734585C168563851 @default.
• W2947734585 hasConceptScore W2947734585C204787440 @default.
• W2947734585 hasConceptScore W2947734585C27081682 @default.
• W2947734585 hasConceptScore W2947734585C2777666782 @default.

• next